Navigation Links
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
Date:4/10/2008

Data Presented at the 10th Annual Superbugs and Superdrugs Conference on

Antibacterials

WATERTOWN, Mass., April 10 /PRNewswire/ -- Enanta Pharmaceuticals, a leader in the development of small molecule anti-infective drugs, today announced the presentation of their breakthrough research program to evaluate a new macrolide-related drug class, Bicyclolides, in the treatment of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and other gram-positive infection pathogens. Enanta's Bicyclolides have also demonstrated strong activity against MRSA strains resistant to vancomycin, Zyvox(R) (linezolid), and CUBICIN(R) (daptomycin).

The oral presentation, "New Bicyclolides Active Against MRSA and VRE," was presented today during the 10th Annual Superbugs and Superdrugs Conference in London, England.

"Previously, MRSA infection was a problem mainly for patients treated in hospitals," said Robert Moellering, M.D., a professor of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. "Now we're seeing MRSA in the general community, creating a tremendous need for a new class of antibiotics with improved safety profile and more convenient administration for use within both hospital as well as community settings. The growing problem of bacterial resistance to many existing drugs also necessitates the development of new classes of compounds to fight the battle."

"Pre-clinical research on these new Bicyclolide compounds revealed activity against MRSA and VRE, even against highly drug-resistant MRSA strains. This was an unexpected finding, because traditional macrolides do not work against these bacteria," explained Yat Sun Or, Ph.D., Senior Vice President of Research and Development at Enanta. "These results are also very exciting, because we have observed activity as good as intravenously-administered vancomycin or Zyvox(R) with oral once-a-day dosing levels of the Bicyclolides. The convenience of oral administration and the safety profile of macrolides as a class represent patient and pharmacoeconomic benefits that could be potentially quite significant, making this program a worthwhile endeavor."

About Enanta's Bicyclolide research program

Bicyclolides posses a reengineered back-bone structure of traditional macrolides, whose benefits include the potential for oral and intravenous administration and limited side-effects. The discovery of Bicyclolides' effectiveness against MRSA and VRE infections is part of Enanta's broad antibiotic research program. Enanta has applied several research strategies to develop these new classes of antibiotics, including innovative medicinal chemistry approaches to create novel and proprietary chemical structures. Enanta has applied its chemistry approach to create promising product pipelines and a vast intellectual property estate.

About MRSA

More than 130,000 people each year need hospital care for MRSA, according to the Centers for Disease Control and Prevention. Staphylococcus aureus is a bacterium that can live harmlessly on human skin and is found in the nose of 20 to 40 percent of healthy individuals, but can sometimes cause infections when exposed to broken skin. MRSA is a particular type of the bacteria that has developed resistance to many antibiotics, including methicillin, making it difficult to treat. Currently, the antibiotic drugs typically administered to MRSA patients are intravenous. This method is expensive and inconvenient, especially for those who acquired the infection in the community and must seek hospital treatment for lengthy intravenous treatment.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. At the heart of Enanta is its commitment to innovative chemistry that surpasses traditional medicinal chemistry approaches. Enanta is developing novel protease and polymerase inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcome bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. Enanta is a privately held company with offices in Watertown, MA. More information about the company can be found at http://www.enanta.com .

Zyvox is a registered trademark of Pfizer Inc. and CUBICIN is a registered trademark of Cubist Pharmaceuticals, Inc.

Enanta Contacts

For Enanta Investor Relations, please contact:

Paul Mellett

617-607-0761

For Enanta Public Relations, please contact MacDougall Biomedical

Communications:

Kari Watson

781-235-3060

kwatson@macbiocom.com


'/>"/>
SOURCE Enanta Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
3. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
4. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
5. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. NPS Reports Successful GATTEX(TM) Extension Study
9. New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
10. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
11. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Jan. 23, 2017 MouthWatch LLC announced today that ... ranked as the best intraoral camera on DentalCompare,s list of ... spot overall. The #1 product was the CollaPlug Absorbable ... intraoral camera was "…incredibly popular because it is by far ... a small sticker price, it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)...  Delcath Systems, Inc. (NASDAQ: DCTH ), ... primary and metastatic liver cancers, today announced that ... Chief Executive Officer of Delcath will be a featured ... Annual Investor Conference at the Boca Raton Resort & ... on Tuesday, January 31, 2017 at 10:30 am Eastern ...
(Date:1/23/2017)... DIEGO , Jan. 23, 2017  Using ... patients at high risk for acute kidney injury ... recommended by globally-recognized care guidelines significantly ... to severe AKI more than 33 percent, according ... in the journal Intensive Care Medicine. ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is proud ... Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , This ... 2008 to address the limitations of fatigue monitoring technologies within the mining industry. ...
(Date:1/23/2017)... Washington, Dc (PRWEB) , ... January 23, 2017 ... ... at American University is taught by healthcare management and evaluation leaders with decades ... from fee-for-service to pay-for-value in the United States healthcare system, there is a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 Sector Summit ... moderated by Inside Indiana Business host Gerry Dick, will feature an employer and ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... has earned organic certification under the USDA National Organic Program (NOP) for its ... process, we have established organic production and handling systems to complement our current ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... the American Society of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and ... Orthopaedic Surgeons (AAOS) and the Cigna Foundation, encourages proposals supporting high quality ...
Breaking Medicine News(10 mins):